Axsome Therapeutics (AXSM) Reports AXS-05 Achieves Primary Endpoint in Phase 2 Trial in Major Depressive Disorder - StreetInsider.com

Submitted by Anonymous (not verified) on Mon, 01/07/2019 - 11:01

Axsome Therapeutics (AXSM) Reports AXS-05 Achieves Primary Endpoint in Phase 2 Trial in Major Depressive Disorder  StreetInsider.comGet instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here. Axsome Therapeutics, Inc. (NASDAQ: AXSM) ...